Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice

Circulation

Volumn 107, Issue 7, 2003, Pages 1009-1016

  Combadière, Christophe ^a,b   Potteaux, Stéphane ^b   Gao, Ji Liang ^a   Esposito, Bruno ^c   Casanova, Saveria ^b   Lee, Eric J ^d   Debré, Patrice ^b   Tedgui, Alain ^c   Murphy, Philip M ^a   Mallat, Ziad ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Atherosclerosis; Inflammation; Leukocytes; Receptors

Indexed keywords

APOLIPOPROTEIN E; CHEMOKINE RECEPTOR CXCR1; COLLAGEN; FRACTALKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA SINUS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHEMOTAXIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DNA POLYMORPHISM; EMBRYO; GENE DISRUPTION; GENE EXPRESSION; KNOCKOUT MOUSE; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; THORACIC AORTA;

ALLELES; ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CHEMOKINES, CX3C; CHEMOTAXIS, LEUKOCYTE; GENE TARGETING; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MONOCYTES; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOKINE; RECEPTORS, HIV;

EID: 0037465557     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000057548.68243.42     Document Type: Article

References (31)

1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
2. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104: 503-516.
3. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.
4. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
5. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217-242.
6. Boring L, Gosling J, Cleary M, et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897.
7. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptordeficient mice. Mol Cell. 1998;2:275-281.
8. Szalai C, Duba J, Prohaszka Z, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD): coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis. 2001;158:233-239.
9. Valdes AM, Wolfe ML, O'Brien EJ, et al. Va164Ile polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification. Arterioscler Throm Vasc Biol. 2002;22:1924-1928.
10. Boisvert WA, Santiago R, Curtiss LK, et al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest. 1998;101:353-363.
11. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane- bound chemokine with a CX3C motif. Nature. 1997;385:640-644.
12. Pan Y, Lloyd C, Zhou H, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature. 1997;387: 611-617.
13. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521-530.
14. Fong AM, Robinson LA, Steeber DA, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998;188:1413-1419.
15. Soriano SG, Amaravadi LS, Wang YF, et al. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol. 2002;125:59-65.
16. Haskell CA, Hancock WW, Salant DJ, et al. Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest. 2001;108:679-688.
17. Jung S, Aliberti J, Graemmel P, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20:4106-4114.
18. Cook DN, Chen SC, Sullivan LM, et al. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol. 2001;21:3159-3165.
19. Greaves DR, Hakkinen T, Lucas AD, et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001;21:923-929.
20. McDermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 2001;89:401-407.
21. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001;97:1925-1928.
22. Combadiere C, Gao J, Tiffany HL, et al. Gene cloning, RNA distribution, and functional expression of mCX3CR1, a mouse chemotactic receptor for the CX3C chemokine fractalkine. Biochem Biophys Res Commun. 1998;253:728-732.
23. Zhou X, Paulsson G, Stemme S, et al. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest. 1998;101:1717-1725.
24. Mallat Z, Corbaz A. Scoazec A, et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001;89:E41-E45.
25. Hansson GK. Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281-291.
26. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680-2690.
27. Smith JD, Trogan E, Ginsberg M, et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoproteine. Proc Natl Acad Sci U S A. 1995;92:8264-8268.
28. Rollins BJ. Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease. J Clin Invest. 2001;108:1269-1271.
29. Huo Y. Weber C, Forlow SB, et al. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest. 2001;108:1307-1314.
30. Cybulsky MI, Iiyama K, Li H. et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107:1255-1262.
31. Little WC, Applegate RJ. The shadows leave a doubt: the angiographic recognition of vulnerable coronary artery plaques. J Am Coll Cardiol. 1999;33:1362-1364.